TARA Protara Therapeutics
- 2.670
- -0.040-1.48%
- 2.700
- +0.030+1.12%
Protara Therapeutics News
Protara Therapeutics(TARA.US) 10% Shareholder Sells US$44,007.97 in Common Stock
$Protara Therapeutics(TARA.US)$ 10% Shareholder Opaleye Management Inc. sold 15,054 shares of common stock on May 30, 31, 2024 at an average price of $2.9233 for a total value of $44,007.97.Source: An
Protara Therapeutics(TARA.US) 10% Shareholder Sells US$130.43K in Common Stock
$Protara Therapeutics(TARA.US)$ 10% Shareholder Opaleye Management Inc. sold 42,800 shares of common stock on May 21, 22, 2024 at an average price of $3.0475 for a total value of $130.43K.Source: Anno
Protara Therapeutics to Present at the TD Cowen 5th Annual Oncology Innovation Summit
Protara Therapeutics(TARA.US) 10% Shareholder Sells US$230.33K in Common Stock
$Protara Therapeutics(TARA.US)$ 10% Shareholder Opaleye Management Inc. sold 70,885 shares of common stock on May 17, 2024 at an average price of $3.2493 for a total value of $230.33K.Source: Announce
Protara Therapeutics(TARA.US) 10% Shareholder Sells US$566.95K in Common Stock
$Protara Therapeutics(TARA.US)$ 10% Shareholder Opaleye Management Inc. sold 182.3K shares of common stock on May 9, 10, 2024 at an average price of $3.11 for a total value of $566.95K.Source: Announc
Watching Protara Therapeutics, Opthea Ltd.; Shares Moving Higher As Traders Circulate Post From 'TipRanks' Suggesting "These 2 'Strong Buy' Penny Stocks Could Surge Over 400%, Says Oppenheimer"
Watching Protara Therapeutics, Opthea Ltd.; Shares Moving Higher As Traders Circulate Post From 'TipRanks' Suggesting "These 2 'Strong Buy' Penny Stocks Could Surge Over 400%, Says Oppenheimer"
Protara: Cash Resources, Private Placement Procceeds Expected to Fund Ops Into 2026 >TARA
Protara: Cash Resources, Private Placement Procceeds Expected to Fund Ops Into 2026 >TARA
Protara Therapeutics 1Q Loss/Shr 97c >TARA
Protara Therapeutics 1Q Loss/Shr 97c >TARA
Lexicon Pharmaceuticals, Bio-Path Holdings, Protara Therapeutics Among Healthcare Movers
Alphabet To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.Susquehanna
Protara Therapeutics (TARA) Receives a Buy From Oppenheimer
Oppenheimer Maintains Outperform on Protara Therapeutics, Raises Price Target to $30
Oppenheimer analyst Leland Gershell maintains Protara Therapeutics with a Outperform and raises the price target from $26 to $30.
Protara Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Protara Therapeutics Is Maintained at Buy by HC Wainwright & Co.
HC Wainwright & Co. : Maintaining the Protara Therapeutics (TARA.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $23.00 to $23.00.
HC Wainwright & Co. : Maintaining the Protara Therapeutics (TARA.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $23.00 to $23.00.
HC Wainwright & Co. Maintains Buy on Protara Therapeutics, Maintains $23 Price Target
HC Wainwright & Co. analyst Andrew Fein maintains Protara Therapeutics with a Buy and maintains $23 price target.
Protara Therapeutics Shares Interim Data From Bladder Cancer Study, Raises $45M Via Equity
Friday, Protara Therapeutics Inc (NASDAQ:TARA) shared data from three-month evaluable carcinoma in situ (CIS) patients treated across TARA-002 program, the company's investigational cell-based therapy
12 Health Care Stocks Moving In Friday's Pre-Market Session
GainersProtara Therapeutics (NASDAQ:TARA) stock increased by 40.3% to $5.64 during Friday's pre-market session. The market value of their outstanding shares is at $64.4 million. Candel Therapeutics (N
Protara Therapeutics Announces Oversubscribed $45 Million Private Placement Financing
NEW YORK, April 05, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that it
Protara Therapeutics Announces Alignment With FDA on Registrational Path Forward for IV Choline Chloride in Patients Dependent on Parenteral Nutrition
New development pathway significantly expands addressable patient population for IV Choline ChlorideIV Choline Chloride has the potential to become the first FDA-approved IV formulation of choline for the 40,000 PN
Protara Therapeutics CMO Resigns, Interim Successor Named
Analysis
Price Target
No Data
